ADS-5102

ADS-5102 Aided Walking Speed in Select MS Patients in INROADS Trial

  An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in multiple sclerosis (MS) patients who had difficulty with this, particularly younger patients with a shorter disease course, the INROADS Phase 3 trial demonstrated. Further clinical work on this investigative…

1st Patient Enrolls in Phase 3 Trial of ADS-5102 as Way of Improving Walking Ability, Adamas Announces

A Phase 3 trial testing an oral once-a-day therapy ā€” ADS-5102 (amantadine) extended release capsules ā€” inĀ multiple sclerosis (MS) patients with walking difficulties has enrolled its first participant, Adamas Pharmaceuticals announced. The multi-center, double-blind study (NCT03436199) will assess ADS-5102 in about 570 such patients at five sites…

#ACTRIMS2017 – Phase 2 Trial Data Shows Better Walking Speeds in MS Patients Using ADS-5102

Results from aĀ Phase 2 proof-of-concept studyĀ ofĀ ADS-5102Ā (amantadineĀ HCl), showing that multiple sclerosis patients givenĀ the extended-release oral treatment improved their walking speed, will be presentedĀ at ACTRIMS 2017Ā this week. Findings in theĀ poster, ā€œA Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment,ā€…

Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties

Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, inĀ multiple sclerosis (MS) patients with difficulties inĀ walking. The trial (NCT02471222),Ā aĀ double-blind, placebo-controlled and two-arm parallel groupĀ study,Ā evaluated ADS-5102 given once dailyĀ at 340 mg, at bedtime, for four…

Adamas Reports Walking Improvement in MS Models with ADS-5102 (Amantadine HCl)

Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the companyā€™s product candidate ADS-5102 can be potentially applied as a treatment for multiple sclerosis (MS) symptoms. MS is a chronic, progressive neurodegenerative autoimmune…